Pretreatment serum uPA and survival in patients with advanced pancreatic cancer

摘要: 4247 Background: Urokinase-type plasminogen activator (uPA) is a serine protease associated with tumor cell migration, angiogenesis, metastasis, and invasion. uPA has been reported to be secreted by tumors, adjacent stromal cells, fibroblasts, proposed as prognostic factor in breast, liver, colon cancers. Methods: This study determined serum levels phase III clinical trial of 149 patients advanced pancreatic cancer. A double-antibody sandwich ELISA (Oncogene Science Diagnostics, Cambridge, MA) was employed determine the pretreatment cancer enrolled randomized, double-blind, placebo-controlled trial. healthy control group consisting 47 males 62 females used uPA. Results: The results showed that were significantly higher female (1.37 ng/mL) compared male (1.15 individuals (p = 0.0002). Within grou...